Trials / Completed
CompletedNCT00456794
12-Week, Double-Blind, Placebo-Controlled Study of 20 and 60 mg/Day Istradefylline in Parkinson's Disease Patients on Levodopa/Carbodopa
A 12-Week, Double-Blind, Placebo-Controlled, Randomized, Multicenter Study of the Efficacy of Doses of 20 and 60 mg/Day Istradefylline as Treatment for Parkinson's Disease in Patients With Motor Response Complications on Levodopa/Carbidopa
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 325 (planned)
- Sponsor
- Kyowa Kirin, Inc. · Industry
- Sex
- All
- Age
- 30 Years
- Healthy volunteers
- Not accepted
Summary
A 12-week, multicenter, double-blind, randomized study designed to evaluate the safety and efficacy of 20 and 60 mg/day istradefylline compared with placebo in subjects with OFF-time phenomena and advanced Parkinson's disease treated with levodopa/carbidopa.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Istradefylline (KW-6002) |
Timeline
- Start date
- 2002-03-01
- Primary completion
- 2003-10-01
- Completion
- 2003-10-01
- First posted
- 2007-04-05
- Last updated
- 2024-04-25
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT00456794. Inclusion in this directory is not an endorsement.